Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy in locally advanced rectal cancer (UNION): early outcomes of a multicenter randomized phase III trial

医学 临床终点 放射治疗 放化疗 结直肠癌 随机对照试验 新辅助治疗 外科 内科学 肿瘤科 癌症 乳腺癌
作者
Zhuofeng Lin,Peipei Zhang,Ping Chi,Yi Xiao,Xiaoyue Xu,A.M. Zhang,Xin Qiu,Jun Wu,Ying Yuan,Zhenning Wang,Xiaomei Qu,Xinyu Li,Xin Nie,Mu Yang,Keke Cai,W.K. Zhang,Yisen Huang,Zhiguang Sun,Z. G. Hou,Chao Ma
出处
期刊:Annals of Oncology [Elsevier BV]
卷期号:35 (10): 882-891 被引量:11
标识
DOI:10.1016/j.annonc.2024.06.015
摘要

•This is the first phase III trial comparing SCRT followed by immunochemotherapy to LCRT followed by chemotherapy in LARC.•Neoadjuvant SCRT followed by CAPOX and camrelizumab significantly improved pCR versus neoadjuvant LCRT followed by CAPOX.•Neoadjuvant SCRT followed by CAPOX and camrelizumab demonstrated promising efficacy in LARC patients with pMMR/MSS.•The treatment arm provides LARC patients with the opportunity for organ preservation and a watch-and-wait strategy.•No unexpected toxicities were observed, and the safety profile of the treatment arm was manageable. BackgroundNeoadjuvant short-course radiotherapy (SCRT) followed by CAPOX and camrelizumab (a programmed cell death protein 1 monoclonal antibody) has shown potential clinical activity for locally advanced rectal cancer (LARC) in a phase II trial. This study aimed to further confirm the efficacy and safety of SCRT followed by CAPOX and camrelizumab compared to long-course chemoradiotherapy (LCRT) followed by CAPOX alone as neoadjuvant treatment for LARC.Patients and methodsIn this randomized, phase III trial, patients with T3-4/N+ rectal adenocarcinoma were randomly assigned (1 : 1) to receive SCRT or long-course chemoradiotherapy (LCRT), followed by two cycles of camrelizumab and CAPOX or CAPOX alone, respectively. After surgery, each arm underwent either six cycles of camrelizumab and CAPOX, followed by up to 17 doses of camrelizumab, or six cycles of CAPOX. The primary endpoint was pathological complete response (pCR) rate (ypT0N0) assessed by a blinded independent review committee. Key secondary endpoints tested hierarchically were 3-year event-free survival (EFS) rate and overall survival (OS).ResultsBetween July 2021 and March 2023, the intention-to-treat population comprised 113 patients in the experimental arm and 118 patients in the control arm, with surgery carried out in 92% and 83.9%, respectively. At data cut-off (11 July 2023), the pCR rates were 39.8% [95% confidence interval (CI) 30.7% to 49.5%] in the experimental arm compared to 15.3% (95% CI 9.3% to 23.0%) in the control arm (difference, 24.6%; odds ratio, 3.7; 95% CI 2.0-6.9; P < 0.001). In each arm, surgical complication rates were 40.0% and 40.8%, and grade ≥3 treatment-related adverse events were 29.2% and 27.2%. Three-year EFS rate and OS continue to mature.ConclusionsIn LARC patients, neoadjuvant SCRT followed by camrelizumab plus CAPOX demonstrated a significantly higher pCR rate than LCRT followed by CAPOX, with a well-tolerated safety profile. SCRT followed by camrelizumab and chemotherapy can be recommended as a neoadjuvant treatment modality for these patients. Neoadjuvant short-course radiotherapy (SCRT) followed by CAPOX and camrelizumab (a programmed cell death protein 1 monoclonal antibody) has shown potential clinical activity for locally advanced rectal cancer (LARC) in a phase II trial. This study aimed to further confirm the efficacy and safety of SCRT followed by CAPOX and camrelizumab compared to long-course chemoradiotherapy (LCRT) followed by CAPOX alone as neoadjuvant treatment for LARC. In this randomized, phase III trial, patients with T3-4/N+ rectal adenocarcinoma were randomly assigned (1 : 1) to receive SCRT or long-course chemoradiotherapy (LCRT), followed by two cycles of camrelizumab and CAPOX or CAPOX alone, respectively. After surgery, each arm underwent either six cycles of camrelizumab and CAPOX, followed by up to 17 doses of camrelizumab, or six cycles of CAPOX. The primary endpoint was pathological complete response (pCR) rate (ypT0N0) assessed by a blinded independent review committee. Key secondary endpoints tested hierarchically were 3-year event-free survival (EFS) rate and overall survival (OS). Between July 2021 and March 2023, the intention-to-treat population comprised 113 patients in the experimental arm and 118 patients in the control arm, with surgery carried out in 92% and 83.9%, respectively. At data cut-off (11 July 2023), the pCR rates were 39.8% [95% confidence interval (CI) 30.7% to 49.5%] in the experimental arm compared to 15.3% (95% CI 9.3% to 23.0%) in the control arm (difference, 24.6%; odds ratio, 3.7; 95% CI 2.0-6.9; P < 0.001). In each arm, surgical complication rates were 40.0% and 40.8%, and grade ≥3 treatment-related adverse events were 29.2% and 27.2%. Three-year EFS rate and OS continue to mature. In LARC patients, neoadjuvant SCRT followed by camrelizumab plus CAPOX demonstrated a significantly higher pCR rate than LCRT followed by CAPOX, with a well-tolerated safety profile. SCRT followed by camrelizumab and chemotherapy can be recommended as a neoadjuvant treatment modality for these patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
TEN110684发布了新的文献求助10
1秒前
科研通AI2S应助科研通管家采纳,获得30
2秒前
北风应助科研通管家采纳,获得10
2秒前
yy完成签到,获得积分10
2秒前
orixero应助科研通管家采纳,获得10
2秒前
科研通AI5应助科研通管家采纳,获得10
2秒前
小蘑菇应助科研通管家采纳,获得10
2秒前
bc应助科研通管家采纳,获得20
2秒前
2秒前
2秒前
mayu发布了新的文献求助10
3秒前
自然怀梦完成签到,获得积分10
5秒前
lucky完成签到 ,获得积分10
5秒前
yan发布了新的文献求助10
6秒前
linus应助TEN110684采纳,获得10
7秒前
希望天下0贩的0应助mayu采纳,获得10
13秒前
18秒前
安安完成签到,获得积分20
19秒前
20秒前
25秒前
NEAU小孩儿发布了新的文献求助10
26秒前
天天快乐应助guozizi采纳,获得10
26秒前
28秒前
YHF2完成签到,获得积分10
28秒前
安陌煜发布了新的文献求助10
30秒前
研友_LJGpan完成签到,获得积分10
32秒前
71发布了新的文献求助10
33秒前
NEAU小孩儿完成签到,获得积分20
34秒前
炫潮浪子完成签到,获得积分10
36秒前
36秒前
科研通AI5应助香蕉新筠采纳,获得10
37秒前
71完成签到,获得积分10
38秒前
Ava应助Aliya采纳,获得10
39秒前
zjz发布了新的文献求助10
43秒前
46秒前
48秒前
zjz完成签到,获得积分10
49秒前
香蕉新筠发布了新的文献求助10
50秒前
忧伤的慕梅完成签到 ,获得积分10
51秒前
包佳梁完成签到,获得积分10
52秒前
高分求助中
【此为提示信息,请勿应助】请按要求发布求助,避免被关 20000
Les Mantodea de Guyane Insecta, Polyneoptera 2500
Computational Atomic Physics for Kilonova Ejecta and Astrophysical Plasmas 500
Technologies supporting mass customization of apparel: A pilot project 450
Mixing the elements of mass customisation 360
Периодизация спортивной тренировки. Общая теория и её практическое применение 310
the MD Anderson Surgical Oncology Manual, Seventh Edition 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 物理 生物化学 纳米技术 计算机科学 化学工程 内科学 复合材料 物理化学 电极 遗传学 量子力学 基因 冶金 催化作用
热门帖子
关注 科研通微信公众号,转发送积分 3782096
求助须知:如何正确求助?哪些是违规求助? 3327562
关于积分的说明 10232109
捐赠科研通 3042513
什么是DOI,文献DOI怎么找? 1670006
邀请新用户注册赠送积分活动 799585
科研通“疑难数据库(出版商)”最低求助积分说明 758825